LT3805233T - N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui - Google Patents

N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui

Info

Publication number: LT3805233T
Authority: LT; Lithuania
Prior art keywords: morpholinooxazolo; hydroxypyrrolidin; methylpyridin; oxazole; carboxamide
Prior art date: 2014-01-13

Application number

LTEP20211096.1T

Other languages

English (en)

Inventor

Venkateshwar GUMMADI

Susanta Samajdar

Original Assignee

Aurigene Oncology Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-13

Filing date

2015-01-12

Publication date

2024-05-10

2015-01-12 Application filed by Aurigene Oncology Limited filed Critical Aurigene Oncology Limited

2024-05-10 Publication of LT3805233T publication Critical patent/LT3805233T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)

LTEP20211096.1T 2014-01-13 2015-01-12 N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui LT3805233T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN158CH2014		2014-01-13
IN3000CH2014		2014-06-20

Publications (1)

Publication Number	Publication Date
LT3805233T true LT3805233T (lt)	2024-05-10

Family

ID=53523587

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP20211096.1T LT3805233T (lt)	2014-01-13	2015-01-12	N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
LTEP18190333.7T LT3466955T (lt)	2014-01-13	2015-01-12	Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
LTEP15735499.4T LT3094329T (lt)	2014-01-13	2015-01-12	Bicikliniai heterociklilo dariniai kaip irak4 inhibitoriai

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
LTEP18190333.7T LT3466955T (lt)	2014-01-13	2015-01-12	Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
LTEP15735499.4T LT3094329T (lt)	2014-01-13	2015-01-12	Bicikliniai heterociklilo dariniai kaip irak4 inhibitoriai

Country Status (31)

Country	Link
US (7)	US9732095B2 (lt)
EP (4)	EP3805233B1 (lt)
JP (5)	JP6479850B2 (lt)
KR (3)	KR102574390B1 (lt)
CN (2)	CN111362966B (lt)
AU (5)	AU2015205374B2 (lt)
BR (1)	BR112016016158B1 (lt)
CA (1)	CA2935887A1 (lt)
CU (1)	CU24389B1 (lt)
CY (2)	CY1121433T1 (lt)
DK (3)	DK3094329T3 (lt)
EA (2)	EA038748B1 (lt)
ES (3)	ES2692852T3 (lt)
FI (1)	FI3805233T3 (lt)
HK (1)	HK1231410A1 (lt)
HR (3)	HRP20240489T1 (lt)
HU (3)	HUE066261T2 (lt)
IL (6)	IL302878B2 (lt)
LT (3)	LT3805233T (lt)
MX (1)	MX359909B (lt)
MY (1)	MY197116A (lt)
NZ (2)	NZ760657A (lt)
PH (2)	PH12016501344A1 (lt)
PL (3)	PL3094329T3 (lt)
PT (3)	PT3805233T (lt)
RS (3)	RS61448B1 (lt)
SG (2)	SG11201605486WA (lt)
SI (3)	SI3094329T1 (lt)
TR (1)	TR201815683T4 (lt)
WO (1)	WO2015104688A1 (lt)
ZA (2)	ZA202007273B (lt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
KR20160115933A (ko)	2014-01-10	2016-10-06	오리진 디스커버리 테크놀로지스 리미티드	Irak4 억제제로서의 인다졸 화합물
EA038748B1 (ru) *	2014-01-13	2021-10-14	Ориджин Дискавери Текнолоджиз Лимитед	Способ получения бициклических гетероциклических производных
BR112018000635A2 (pt) *	2015-07-15	2018-09-18	Aurigene Discovery Tech Ltd	compostos aza substituídos como inibidores irak-4
US10065946B2 (en)	2015-08-04	2018-09-04	Rigel Pharmaceuticals, Inc.	Benzazole compounds and methods for making and using the compounds
WO2017148902A1 (de)	2016-03-03	2017-09-08	Bayer Pharma Aktiengesellschaft	Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
MX2019011158A (es)	2017-03-31	2019-10-17	Aurigene Discovery Tech Ltd	Compuestos y composiciones para tratar trastornos hematologicos.
IL273432B (en)	2017-09-22	2022-09-01	Kymera Therapeutics Inc	Protein compounds and their uses
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
BR112020008214A2 (pt) *	2017-10-31	2020-10-27	Curis, Inc.	compostos e composições para tratar distúrbios hematológicos
US11065231B2 (en)	2017-11-17	2021-07-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	IRAK joints and used in them
EP3737666A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	PROTEIN DEGRADANTS AND USES THEREOF
US11512080B2 (en)	2018-01-12	2022-11-29	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
EP3305786A3 (de)	2018-01-22	2018-07-25	Bayer CropScience Aktiengesellschaft	Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
AU2019220632B2 (en)	2018-02-14	2024-02-22	Dana-Farber Cancer Institute, Inc.	IRAK degraders and uses thereof
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
TWI842978B (zh)	2018-07-13	2024-05-21	美商基利科學股份有限公司	衍生物
CA3108065A1 (en)	2018-07-31	2020-02-06	Loxo Oncology, Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP2022516401A (ja)	2018-11-30	2022-02-28	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
JP7576552B2 (ja) *	2019-01-18	2024-10-31	バイオジェン・エムエイ・インコーポレイテッド	イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用
WO2021004533A1 (zh) *	2019-07-10	2021-01-14	南京明德新药研发有限公司	作为irak4和btk多靶点抑制剂的噁唑类化合物
JP7573596B2 (ja)	2019-07-23	2024-10-25	ブリストル－マイヤーズスクイブカンパニー	Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2021066559A1 (en)	2019-10-02	2021-04-08	Kainos Medicine, Inc.	N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
EP4076520A4 (en)	2019-12-17	2024-03-27	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
US11591332B2 (en)	2019-12-17	2023-02-28	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
CN115715194A (zh)	2020-04-04	2023-02-24	辉瑞公司	治疗冠状病毒疾病2019的方法
BR112022019987A2 (pt)	2020-04-07	2022-11-22	Bayer Ag	Tiazolpiridinas substituídas, seus sais e uso dos mesmos como substâncias herbicidamente ativas
WO2021222366A1 (en) *	2020-04-28	2021-11-04	Kymera Therapeutics, Inc.	Irak inhibitors and uses thereof
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
US20230310444A1 (en) *	2020-08-03	2023-10-05	Curis, Inc.	Compositions and methods for treating diseases and disorders
US12064421B2 (en)	2020-11-02	2024-08-20	Boehringer Ingelheim International Gmbh	Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
MX2023005591A (es) *	2020-11-18	2023-05-29	Curis Inc	Metodos de tratamiento de enfermedades y trastornos.
WO2022135338A1 (zh) *	2020-12-25	2022-06-30	南京明德新药研发有限公司	酰胺噁唑类化合物
IL308314A (en)	2021-05-07	2024-01-01	Kymera Therapeutics Inc	CDK2 compounds and their uses
TW202328150A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh)	2021-09-07	2023-07-16	德商拜耳廠股份有限公司	經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
WO2023116866A1 (zh) *	2021-12-23	2023-06-29	杭州多域生物技术有限公司	一种五元并六元化合物、制备方法、药物组合物和应用
TW202330546A (zh) *	2021-12-31	2023-08-01	香港商愛科諾生物醫藥(香港)有限公司	具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用
TW202339738A (zh)	2022-01-31	2023-10-16	美商凱麥拉醫療公司	Irak降解物及其用途
US20240252656A1 (en) *	2022-10-13	2024-08-01	Kymera Therapeutics, Inc.	Salt forms of irak4 degraders
WO2024092011A1 (en) *	2022-10-25	2024-05-02	Kymera Therapeutics, Inc.	Irak degraders and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59010701D1 (de)	1990-05-18	1997-05-22	Hoechst Ag	Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE10023486C1 (de)	2000-05-09	2002-03-14	Schering Ag	Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
EP1581539A4 (en) *	2003-01-03	2007-09-19	Bristol Myers Squibb Co	NEW TYROSINE KINASE HEMMER
US7651469B2 (en)	2003-04-25	2010-01-26	Cook Incorporated	Low friction coated marked wire guide for over the wire insertion of a catheter
GEP20074236B (en)	2003-05-01	2007-11-12	Bristol Myers Squibb Co	Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
WO2004103954A1 (ja)	2003-05-20	2004-12-02	Ajinomoto Co., Inc.	アミド誘導体
WO2004108133A2 (en)	2003-06-05	2004-12-16	Vertex Pharmaceuticals Incorporated	Modulators of vr1 receptor
EP1493795A1 (de)	2003-07-04	2005-01-05	Collano AG	Klebstoffzusammensetzung
CA2541299A1 (en)	2003-10-07	2005-04-14	Renovis, Inc.	Amide compounds as ion channel ligands and uses thereof
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
CA2563941C (en)	2004-04-22	2014-10-07	Bayer Cropscience Lp	Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions
US7906533B2 (en)	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655297A1 (en)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006053227A2 (en)	2004-11-10	2006-05-18	Synta Pharmaceuticals Corp.	Il-12 modulatory compounds
MX2007007227A (es)	2004-12-17	2007-08-21	Lilly Co Eli	Derivados de tiazolopiridinona como antagonistas del receptor mch.
MX2007007226A (es)	2004-12-17	2007-08-21	Lilly Co Eli	Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
EP1674467A1 (en)	2004-12-22	2006-06-28	4Sc Ag	2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
US7820821B2 (en)	2006-02-10	2010-10-26	Transtech Pharma, Inc.	Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
GB0606429D0 (en)	2006-03-30	2006-05-10	Novartis Ag	Organic compounds
JP5255559B2 (ja)	2006-03-31	2013-08-07	アボット・ラボラトリーズ	インダゾール化合物
WO2007121154A2 (en)	2006-04-11	2007-10-25	Janssen Pharmaceutica, N.V.	Substituted benzothiazole kinase inhibitors
WO2008030579A2 (en) *	2006-09-07	2008-03-13	Biogen Idec Ma Inc.	Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
CN101616910A (zh) *	2006-09-07	2009-12-30	比奥根艾迪克Ma公司	作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物
WO2008061109A2 (en)	2006-11-15	2008-05-22	Forest Laboratories Holdings Limited	Indazole derivatives useful as melanin concentrating receptor ligands
WO2008073825A1 (en)	2006-12-08	2008-06-19	Exelixis, Inc.	Lxr and fxr modulators
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CA2690557A1 (en)	2007-06-14	2008-12-24	Schering Corporation	Imidazopyrazines as protein kinase inhibitors
CA2690619A1 (en)	2007-07-16	2009-01-22	Abbott Laboratories	Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
WO2009011850A2 (en)	2007-07-16	2009-01-22	Abbott Laboratories	Novel therapeutic compounds
EA201070238A1 (ru)	2007-08-08	2010-08-30	Мерк Сероно С.А.	Соединения пиримидина
EP2252617A1 (en)	2008-02-13	2010-11-24	CGI Pharmaceuticals, Inc.	6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
EP2311842A3 (en)	2008-06-24	2011-07-13	Takeda Pharmaceutical Company Limited	PI3K/M TOR inhibitors
US8716312B2 (en)	2008-11-19	2014-05-06	Merck Sharp & Dohme Corporation	Inhibitors of diacylglycerol acyltransferase
WO2010071819A1 (en) *	2008-12-19	2010-06-24	Schering Corporation	Bicyclic heterocyclic derivatives and methods of use thereof
SG172382A1 (en)	2008-12-23	2011-07-28	Hoffmann La Roche	Dihydropyridone ureas as p2x7 modulators
US8765747B2 (en)	2009-06-12	2014-07-01	Dana-Farber Cancer Institute, Inc.	Fused 2-aminothiazole compounds
US20130035326A1 (en)	2009-08-19	2013-02-07	Ambit Biosciences Corporation	Biaryl compounds and methods of use thereof
JP2012254939A (ja)	2009-10-07	2012-12-27	Astellas Pharma Inc	オキサゾール化合物
CA2777565C (en)	2009-10-13	2019-06-18	Ligand Pharmaceuticals Inc.	Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses
AU2011242711C1 (en)	2010-04-22	2016-04-21	Janssen Pharmaceutica Nv	Indazole compounds useful as ketohexokinase inhibitors
JP2013525453A (ja)	2010-04-30	2013-06-20	メルク・シャープ・エンド・ドーム・コーポレイション	ホスホイノシチド依存性キナーゼ１（ｐｄｋ１）阻害薬
WO2011163640A1 (en)	2010-06-24	2011-12-29	Chemocentryx, Inc.	C5ar antagonists
JP5985473B2 (ja)	2010-07-13	2016-09-06	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
EP2640708A1 (en)	2010-11-19	2013-09-25	Ligand Pharmaceuticals Inc.	Heterocycle amines and uses thereof
SI2655357T1 (sl)	2010-12-20	2016-10-28	Merck Serono S.A.	Derivati indazolil triazola kot zaviralci IRAK
AU2012242926B2 (en)	2011-04-12	2016-07-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013042137A1 (en) *	2011-09-19	2013-03-28	Aurigene Discovery Technologies Limited	Bicyclic heterocycles as irak4 inhibitors
PT2766359T (pt)	2011-10-14	2016-07-14	Ambit Biosciences Corp	Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
EP2768509B1 (en)	2011-10-20	2017-03-22	Glaxosmithkline LLC	Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013066729A1 (en) *	2011-10-31	2013-05-10	Merck Sharp & Dohme Corp.	Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
GB201119401D0 (en)	2011-11-10	2011-12-21	Ucb Pharma Sa	Therapeutic agents
KR101385603B1 (ko)	2012-05-17	2014-04-21	한국원자력의학원	벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en)	2012-06-29	2014-01-03	Hanmi Pharm. Co., Ltd.	Fused pyrimidine derivatives having inhibitory activity on fms kinases
EP2872144A4 (en)	2012-07-11	2015-12-02	Nimbus Iris Inc	IRAQ INHIBITOR AND USES THEREOF
US9334249B2 (en)	2012-11-03	2016-05-10	Boehringer Ingelheim International Gmbh	Inhibitors of cytomegalovirus
EP2999470B1 (en)	2013-05-22	2017-08-16	Children's Hospital Medical Center	Combination therapy for mds
TWI652014B (zh)	2013-09-13	2019-03-01	美商艾佛艾姆希公司	雜環取代之雙環唑殺蟲劑
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
KR20160115933A (ko)	2014-01-10	2016-10-06	오리진 디스커버리 테크놀로지스 리미티드	Irak4 억제제로서의 인다졸 화합물
EA038748B1 (ru)	2014-01-13	2021-10-14	Ориджин Дискавери Текнолоджиз Лимитед	Способ получения бициклических гетероциклических производных
SG11201606367YA (en)	2014-02-06	2016-09-29	Abbvie Inc	6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
EP3157521A4 (en)	2014-06-20	2018-02-14	Aurigene Discovery Technologies Limited	Substituted indazole compounds as irak4 inhibitors
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es)	2015-04-30	2016-11-30	Bayer Pharma AG	Combinaciones de inhibidores de irak4
CU20180006A7 (es)	2015-07-15	2018-06-05	Aurigene Discovery Tech Ltd	Compuestos de indazaol y azaindazol como inhibidores de irak-4
BR112018000635A2 (pt)	2015-07-15	2018-09-18	Aurigene Discovery Tech Ltd	compostos aza substituídos como inibidores irak-4
US10065946B2 (en)	2015-08-04	2018-09-04	Rigel Pharmaceuticals, Inc.	Benzazole compounds and methods for making and using the compounds
US20210292843A1 (en)	2016-10-28	2021-09-23	Children's Hospital Medical Center	Treatment of diseases associated with activated irak
MX2019011158A (es)	2017-03-31	2019-10-17	Aurigene Discovery Tech Ltd	Compuestos y composiciones para tratar trastornos hematologicos.
BR112020008214A2 (pt)	2017-10-31	2020-10-27	Curis, Inc.	compostos e composições para tratar distúrbios hematológicos
JP2022516401A (ja)	2018-11-30	2022-02-28	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
US20230310444A1 (en)	2020-08-03	2023-10-05	Curis, Inc.	Compositions and methods for treating diseases and disorders
MX2023005591A (es)	2020-11-18	2023-05-29	Curis Inc	Metodos de tratamiento de enfermedades y trastornos.
KR20240004476A (ko)	2021-04-08	2024-01-11	쿠리스 인코퍼레이션	암 치료를 위한 병용 요법
WO2023220227A1 (en)	2022-05-11	2023-11-16	Curis, Inc.	Treating diseases and disorders with irak4-modifying compounds

2015
- 2015-01-12 EA EA201891917A patent/EA038748B1/ru unknown
- 2015-01-12 US US15/111,000 patent/US9732095B2/en active Active
- 2015-01-12 SI SI201530477T patent/SI3094329T1/sl unknown
- 2015-01-12 MY MYPI2021007377A patent/MY197116A/en unknown
- 2015-01-12 PT PT202110961T patent/PT3805233T/pt unknown
- 2015-01-12 IL IL302878A patent/IL302878B2/en unknown
- 2015-01-12 RS RS20210039A patent/RS61448B1/sr unknown
- 2015-01-12 RS RS20240415A patent/RS65437B1/sr unknown
- 2015-01-12 CN CN202010147212.8A patent/CN111362966B/zh active Active
- 2015-01-12 KR KR1020227014075A patent/KR102574390B1/ko active IP Right Grant
- 2015-01-12 ES ES15735499.4T patent/ES2692852T3/es active Active
- 2015-01-12 TR TR2018/15683T patent/TR201815683T4/tr unknown
- 2015-01-12 PL PL15735499T patent/PL3094329T3/pl unknown
- 2015-01-12 LT LTEP20211096.1T patent/LT3805233T/lt unknown
- 2015-01-12 FI FIEP20211096.1T patent/FI3805233T3/fi active
- 2015-01-12 CN CN201580013752.4A patent/CN106456619B/zh active Active
- 2015-01-12 MX MX2016009013A patent/MX359909B/es active IP Right Grant
- 2015-01-12 EP EP20211096.1A patent/EP3805233B1/en active Active
- 2015-01-12 HU HUE20211096A patent/HUE066261T2/hu unknown
- 2015-01-12 KR KR1020167021713A patent/KR102392684B1/ko active IP Right Grant
- 2015-01-12 ES ES18190333T patent/ES2846678T3/es active Active
- 2015-01-12 CA CA2935887A patent/CA2935887A1/en active Pending
- 2015-01-12 HU HUE15735499A patent/HUE041926T2/hu unknown
- 2015-01-12 DK DK15735499.4T patent/DK3094329T3/en active
- 2015-01-12 BR BR112016016158-0A patent/BR112016016158B1/pt active IP Right Grant
- 2015-01-12 PL PL18190333T patent/PL3466955T3/pl unknown
- 2015-01-12 SG SG11201605486WA patent/SG11201605486WA/en unknown
- 2015-01-12 LT LTEP18190333.7T patent/LT3466955T/lt unknown
- 2015-01-12 IL IL311677A patent/IL311677A/en unknown
- 2015-01-12 EA EA201691428A patent/EA031913B1/ru unknown
- 2015-01-12 WO PCT/IB2015/050217 patent/WO2015104688A1/en active Application Filing
- 2015-01-12 EP EP23214923.7A patent/EP4353324A3/en active Pending
- 2015-01-12 IL IL294895A patent/IL294895B2/en unknown
- 2015-01-12 PT PT15735499T patent/PT3094329T/pt unknown
- 2015-01-12 HU HUE18190333A patent/HUE052252T2/hu unknown
- 2015-01-12 EP EP15735499.4A patent/EP3094329B1/en active Active
- 2015-01-12 SG SG10201811204RA patent/SG10201811204RA/en unknown
- 2015-01-12 PL PL20211096.1T patent/PL3805233T3/pl unknown
- 2015-01-12 CU CU2016000111A patent/CU24389B1/es unknown
- 2015-01-12 DK DK20211096.1T patent/DK3805233T3/da active
- 2015-01-12 IL IL284952A patent/IL284952B/en unknown
- 2015-01-12 HR HRP20240489TT patent/HRP20240489T1/hr unknown
- 2015-01-12 KR KR1020237029626A patent/KR20230129622A/ko not_active Application Discontinuation
- 2015-01-12 SI SI201532008T patent/SI3805233T1/sl unknown
- 2015-01-12 SI SI201531483T patent/SI3466955T1/sl unknown
- 2015-01-12 JP JP2016563278A patent/JP6479850B2/ja active Active
- 2015-01-12 RS RS20181355A patent/RS58024B1/sr unknown
- 2015-01-12 NZ NZ760657A patent/NZ760657A/en unknown
- 2015-01-12 NZ NZ722019A patent/NZ722019A/en unknown
- 2015-01-12 AU AU2015205374A patent/AU2015205374B2/en active Active
- 2015-01-12 DK DK18190333.7T patent/DK3466955T3/da active
- 2015-01-12 LT LTEP15735499.4T patent/LT3094329T/lt unknown
- 2015-01-12 ES ES20211096T patent/ES2975436T3/es active Active
- 2015-01-12 EP EP18190333.7A patent/EP3466955B1/en active Active
- 2015-01-12 PT PT181903337T patent/PT3466955T/pt unknown
2016
- 2016-07-03 IL IL246575A patent/IL246575B/en active IP Right Grant
- 2016-07-07 PH PH12016501344A patent/PH12016501344A1/en unknown
2017
- 2017-05-24 HK HK17105239.1A patent/HK1231410A1/zh unknown
- 2017-08-02 US US15/667,173 patent/US10047104B2/en active Active
2018
- 2018-08-03 US US16/054,512 patent/US10640517B2/en active Active
- 2018-10-30 HR HRP20181795TT patent/HRP20181795T1/hr unknown
- 2018-11-20 AU AU2018267569A patent/AU2018267569B2/en active Active
- 2018-12-21 CY CY20181101382T patent/CY1121433T1/el unknown
2019
- 2019-02-06 JP JP2019019229A patent/JP6750053B2/ja active Active
- 2019-12-11 IL IL271364A patent/IL271364B/en unknown
- 2019-12-17 AU AU2019283795A patent/AU2019283795B2/en active Active
2020
- 2020-02-19 US US16/795,394 patent/US10995100B2/en active Active
- 2020-03-13 PH PH12020500529A patent/PH12020500529A1/en unknown
- 2020-06-25 JP JP2020109507A patent/JP6977111B2/ja active Active
- 2020-11-23 ZA ZA2020/07273A patent/ZA202007273B/en unknown
- 2020-11-23 ZA ZA2020/07274A patent/ZA202007274B/en unknown
2021
- 2021-01-19 HR HRP20210094TT patent/HRP20210094T1/hr unknown
- 2021-01-29 CY CY20211100076T patent/CY1123936T1/el unknown
- 2021-04-30 US US17/245,611 patent/US11691987B2/en active Active
- 2021-06-08 AU AU2021203761A patent/AU2021203761B2/en active Active
- 2021-11-10 JP JP2021183016A patent/JP7262553B2/ja active Active
2023
- 2023-04-11 JP JP2023063800A patent/JP2023085526A/ja active Pending
- 2023-04-28 US US18/141,008 patent/US11981685B2/en active Active
- 2023-09-01 AU AU2023222987A patent/AU2023222987A1/en active Pending
2024
- 2024-04-08 US US18/629,313 patent/US20240294547A1/en active Pending

Also Published As

Publication number	Publication date
EP3805233A1 (en)	2021-04-14
CU24389B1 (es)	2019-04-04
PH12016501344A1 (en)	2016-08-15
TR201815683T4 (tr)	2018-11-21
MY197116A (en)	2023-05-26
ZA202007273B (en)	2023-11-29
IL284952B (en)	2022-08-01
BR112016016158A2 (pt)	2017-08-08
HRP20181795T1 (hr)	2019-01-25
US20180370988A1 (en)	2018-12-27
IL294895B2 (en)	2023-10-01
HRP20210094T1 (hr)	2021-03-05
HK1231410A1 (zh)	2017-12-22
HUE041926T2 (hu)	2019-06-28
JP2019077729A (ja)	2019-05-23
US20180022758A1 (en)	2018-01-25
EP3805233B1 (en)	2024-03-06
IL302878B2 (en)	2024-09-01
IL271364B (en)	2021-08-31
EA201691428A1 (ru)	2016-12-30
IL284952A (en)	2021-08-31
CN111362966B (zh)	2022-03-11
EA201891917A1 (ru)	2019-02-28
KR102392684B1 (ko)	2022-04-29
EP3094329B1 (en)	2018-09-26
SI3094329T1 (sl)	2019-02-28
JP6750053B2 (ja)	2020-09-02
PH12020500529A1 (en)	2021-07-26
IL294895B1 (en)	2023-06-01
PL3094329T3 (pl)	2019-03-29
ES2975436T3 (es)	2024-07-05
IL311677A (en)	2024-05-01
JP6479850B2 (ja)	2019-03-06
AU2021203761A1 (en)	2021-07-08
CN106456619A (zh)	2017-02-22
HRP20240489T1 (hr)	2024-07-05
US11981685B2 (en)	2024-05-14
AU2015205374A1 (en)	2016-07-28
AU2019283795A1 (en)	2020-01-16
JP2023085526A (ja)	2023-06-20
NZ722019A (en)	2022-07-01
RS65437B1 (sr)	2024-05-31
CY1123936T1 (el)	2022-05-27
LT3466955T (lt)	2021-02-25
PL3466955T3 (pl)	2021-06-28
EA038748B1 (ru)	2021-10-14
CU20160111A7 (es)	2017-03-03
IL271364A (en)	2020-01-30
SI3466955T1 (sl)	2021-05-31
SG11201605486WA (en)	2016-08-30
KR20220061266A (ko)	2022-05-12
RS58024B1 (sr)	2019-02-28
DK3805233T3 (da)	2024-04-15
PT3466955T (pt)	2021-01-29
US10640517B2 (en)	2020-05-05
HUE052252T2 (hu)	2021-04-28
EA031913B1 (ru)	2019-03-29
AU2019283795B2 (en)	2021-04-01
AU2018267569B2 (en)	2019-09-26
JP6977111B2 (ja)	2021-12-08
US10047104B2 (en)	2018-08-14
JP2017502088A (ja)	2017-01-19
JP2020164546A (ja)	2020-10-08
LT3094329T (lt)	2018-11-26
BR112016016158B1 (pt)	2022-12-13
US9732095B2 (en)	2017-08-15
IL294895A (en)	2022-09-01
WO2015104688A1 (en)	2015-07-16
US10995100B2 (en)	2021-05-04
EP3094329A4 (en)	2017-05-31
MX359909B (es)	2018-10-16
AU2021203761B2 (en)	2023-06-01
FI3805233T3 (fi)	2024-04-17
ES2692852T3 (es)	2018-12-05
IL246575B (en)	2019-12-31
ZA202007274B (en)	2023-11-29
CN106456619B (zh)	2020-03-27
SG10201811204RA (en)	2019-01-30
AU2015205374B2 (en)	2018-08-23
US20240294547A1 (en)	2024-09-05
PT3094329T (pt)	2018-11-26
US20220056046A1 (en)	2022-02-24
DK3094329T3 (en)	2018-11-19
HUE066261T2 (hu)	2024-07-28
DK3466955T3 (da)	2021-02-01
MX2016009013A (es)	2017-01-23
PL3805233T3 (pl)	2024-06-10
EP3466955A1 (en)	2019-04-10
JP2022024021A (ja)	2022-02-08
CY1121433T1 (el)	2020-05-29
EP4353324A3 (en)	2024-07-03
EP3466955B1 (en)	2020-12-16
AU2023222987A1 (en)	2023-09-21
NZ760657A (en)	2022-07-01
KR20160115934A (ko)	2016-10-06
CN111362966A (zh)	2020-07-03
US20230331740A1 (en)	2023-10-19
US20200190112A1 (en)	2020-06-18
JP7262553B2 (ja)	2023-04-21
CA2935887A1 (en)	2015-07-16
US20160340366A1 (en)	2016-11-24
SI3805233T1 (sl)	2024-07-31
IL246575A0 (en)	2016-08-31
EP4353324A2 (en)	2024-04-17
AU2018267569A1 (en)	2018-12-06
KR102574390B1 (ko)	2023-09-04
ES2846678T3 (es)	2021-07-28
US11691987B2 (en)	2023-07-04
IL302878A (en)	2023-07-01
KR20230129622A (ko)	2023-09-08
EP3094329A1 (en)	2016-11-23
RS61448B1 (sr)	2021-03-31
PT3805233T (pt)	2024-04-15
IL302878B1 (en)	2024-05-01

Publication	Publication Date	Title
RS65437B1 (sr)	2024-05-31	(r) i (s) enantiomeri n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oksazol-karboksamida kao inhibitori irak4 za lečenje kancera
HK1247922A1 (zh)	2018-10-05	用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
HK1254358A1 (zh)	2019-07-19	用於治療突觸核蛋白病的藥劑、用途和方法
PH12016501972A1 (en)	2016-12-19	Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
IL255509B (en)	2021-04-29	Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
MA39986A (fr)	2017-03-01	Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
IL261015B (en)	2021-10-31	History of methylamine as lysyl oxidase inhibitors for cancer treatment
EP3286311A4 (en)	2018-11-21	Method for the treatment of malignancies
EP3256218A4 (en)	2018-08-08	Kdm1a inhibitors for the treatment of disease
EP3374502A4 (en)	2019-07-10	METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3242947A4 (en)	2018-08-08	Method for the treatment of malignancies
IL249502B (en)	2020-09-30	New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
EP3302485A4 (en)	2019-02-27	CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNOMES
MX2018005987A (es)	2018-11-29	Compuestos heterociclicos para el tratamiento de enfermedades.
EP3169405A4 (en)	2018-01-24	Methods, compounds, and compositions for the treatment of musculoskeletal diseases
HK1258999A1 (zh)	2019-11-22	用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物
EP3148570A4 (en)	2018-02-14	Pharmaceutical composition for preventing or treating skin rash
HK1251476A1 (zh)	2019-02-01	用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
EP3148538A4 (en)	2018-01-17	Cenicriviroc for the treatment of hiv-2 infection
AU2015901799A0 (en)	2015-05-28	Composition for the treatment of skin conditions
EP3125903A4 (en)	2017-11-15	Method for use of homopiperazinium compounds in the treatment of cancer